Healthcare Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), 22nd Century Group (NYSEMKT:XXII), TherapeuticsMD (NYSEMKT:TXMD), Opexa Therapeutics (NASDAQ:OPXA)

Aegerion Pharmaceuticals (NASDAQ:AEGR) Insider Mark Sumeray sold 2,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $51.34, for a total value of $102,680.00. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares after opening at $55.21 on last trade day and at the end of the day closed at $52.34. Company price to sales ratio in past twelve months was calculated as 31.62 and price to cash ratio as 12.15. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)showed a positive weekly performance of 1.32%.

22nd Century Group (NASDAQ:XXII)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a research note issued to investors on Monday, American Banking News reports. They currently have a $8.00 target price on the stock. Chardan Capital’s price target points to a potential upside of 73.91% from the company’s current price. 22nd Century Group Inc (NYSEMKT:XXII) shares fell -12.87% in last trading session and ended the day on $3.79. XXII return on equity ratio is recorded as 427.90% and its return on assets is -468.20%. 22nd Century Group Inc (NYSEMKT:XXII) yearly performance is 321.11%.

TherapeuticsMD Inc (NYSEMKT:TXMD):Launch of vitaMedMD’s newest prescription prenatal multivitamin, vitaPearl, adding to prenatal line consisting of vitaMedMD One Rx, vitaMedMD Plus Rx, and vitaMedMD RediChew Rx.VitaPearl is pearl-shaped softgel that is smallest complete prescription prenatal multivitamin and first to contain vitaMedMD’s proprietary ingredients of FOLMAX , FePlus , iron combination containing a chelated iron, and pur-DHA among its14 vitamins and minerals. TherapeuticsMD Inc (NYSEMKT:TXMD) shares moved down -7.40% in last trading session and was closed at $7.38, while trading in range of $7.00 – $7.93. TherapeuticsMD Inc (NYSEMKT:TXMD) year to date (YTD) performance is 41.65%.

Opexa Therapeutics Inc (NASDAQ:OPXA), reported financial results for the year ended December 31, 2013, and provided an overview of recent corporate developments. Reported cash and cash equivalents of $23,644,542 as of December 31, 2013; Eliminated debt on Opexa’s consolidated balance sheet through the conversion into common stock of the July 2012 convertible secured promissory notes in an aggregate principal amount of $4.1 million, and unencumbered all of our intellectual property and physical assets previously pledged as collateral; Strengthened the team with the addition of several talented individuals dedicated to furthering the Company’s development initiatives, including enhancing the manufacturing and delivery of Tcelna; and Laid the foundation to explore potential disease indications beyond MS that could be addressed through use of our T-cell platform. Opexa Therapeutics Inc (NASDAQ:OPXA) weekly performance is 3.63%. On last trading day company shares ended up $2.00. Opexa Therapeutics Inc (NASDAQ:OPXA)distance from 50-day simple moving average (SMA50) is 10.89%.